Advertisement

Topics

Adamas to Present at Upcoming BAML Investor Conference

20:00 EDT 12 May 2019 | Globe Newswire

EMERYVILLE, Calif., May 13, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Company’s Founder, Chairman and Chief Executive, is scheduled to present at the following investor conference:

  • Bank of America Merrill Lynch (BAML) 2019 Health Care Conference on Wednesday, May 15 at 1:40 p.m. EDT (10:40 a.m. PDT)

The presentation will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. An archived version of the webcast will be available via replay for 30 days following the presentations.

About Adamas Pharmaceuticals, Inc.

Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.

Contact:

Investors:
Peter Vozzo
Managing Director, Westwicke
443-213-0505
peter.vozzo@westwicke.com

Media:
Sarah Mathieson
Vice President of Corporate Communications
510-450-3528
smathieson@adamaspharma.com

Adamas Pharmaceuticals Logo

NEXT ARTICLE

More From BioPortfolio on "Adamas to Present at Upcoming BAML Investor Conference"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...